Quality indicators for the management of osteoporosis in vulnerable elders

Annals of Internal Medicine

Volumn 135, Issue 8 I, 2001, Pages 722-730

  Grossman, J M ^a   MacLean, C H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CALCIUM; CORTICOSTEROID; ESTROGEN; ETIDRONIC ACID; RALOXIFENE; TESTOSTERONE; VITAMIN D;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEALTH CARE QUALITY; HIGH RISK POPULATION; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; KINESIOTHERAPY; MALE; META ANALYSIS; OSTEOPOROSIS; PATIENT EDUCATION; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

EID: 0035899847     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-135-8_part_2-200110161-00011     Document Type: Article

References (104)

1. Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis
2. Osteoporosis: Review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Introduction
3. A model of lifetime osteoporosis impact
4. Prevalence and severity of vertebral fracture: The Saunders County Bone Quality Study
5. Prevalent vertebral deformities: Relationship to bone mineral density and spinal osteophytosis in elderly men and women
6. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Foundation
7. Assessing care of vulnerable elders: Methods for developing quality indicators
8. Exercise and other factors in the prevention of hip fracture: The Leisure World study
9. Factors associated with appendicular bone mass in older women
10. Risk factors for hip fracture in white women
11. Calcium intake and bone mass: A quantitative review of the evidence
12. Fractured neck of femur. Prevention and management. Summary and recommendations of a report of the Royal College of Physicians
13. Clinical practice guidelines for the diagnosis and management of osteoporosis. Scientific Advisory Board, Osteoporosis Society of Canada
14. Hormone therapy to prevent disease and prolong life in postmenopausal women
15. Treatment of postmenopausal osteoporosis with transdermal estrogen
16. Effect of 10 years' hormone replacement therapy on bone mineral content in postmenopausal women
17. Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment
18. Vitamin D and HRT: No benefit additional to that of HRT alone in prevention of bone loss in early postmenopausal women. A 2.5-year randomized placebo-controlled study
19. Reversal of postmenopausal vertebral bone loss by oestrogen and progestogen: A double blind placebo controlled study
20. Magnitude and pattern of skeletal response to long term continuous and cyclic sequential oestrogen/progestin treatment
21. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy
22. The minimum effective dose of estrogen for prevention of postmenopausal bone loss
23. Estrogen therapy arrests bone loss in elderly women
24. Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium
25. Hormone replacement therapy increases trabecular and cortical bone density in osteoporotic women
26. Prevention of spinal osteoporosis in oophorectomised women
27. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen
28. The risk of hip fracture in postmenopausal females with or without estrogen drug exposure
29. Menopausal estrogen therapy and hip fractures
30. Long-term estrogen replacement therapy prevents bone loss and fractures
31. Fracture protection provided by long-term estrogen treatment
32. An epidemiologic study of hip fracture in postmenopausal women
33. Post-menopausal oestrogens protect against fractures of hip and distal radius. A case-control study
34. Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study
35. The effect of postmenopausal estrogen therapy on bone density in eldery women
36. Estrogen replacement therapy and fractures in older women
37. Hormone replacement therapy and the risk for first hip fracture. A prospective, population-based cohort study
38. Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo study
39. The effect of estrogen dose on postmenopausal bone loss
40. Aetiology and presenting symptoms in male osteoporosis
41. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. American College of Rheumatology Task Force on Osteoporosis Guidelines
42. Exercise therapy for osteoporosis: Results of a randomised controlled trial
43. Therapeutic exercise in the prevention of bone loss. A controlled trial with women after menopause
44. Additive effects of weight-bearing exercise and estrogen on bone mineral density in older women
45. Past and recent physical activity and risk of hip fracture
46. Axial bone mass in older women
47. Evaluation of a program for rehabilitation of osteoporotic patients (PRO): 4-Year follow-up
48. Prevention and management of osteoporosis: Consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 5. Physical activity as therapy for osteoporosis
49. Effect of calcium supplementation on bone loss in postmenopausal women
50. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women
51. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: A randomized controlled trial
52. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis
53. Treatment of postmenopausal osteoporosis with calcitriol or calcium
54. Vitamin D3 and calcium to prevent hip fractures in the elderly women
55. Clinical, biochemical and histological results of a double-blind trial with 1,25-dihydroxyvitamin D3, estradiol and placebo in post-menopausal osteoporosis
56. Alfacalcidol (alpha D3) and calcium in osteoporosis
57. Effects of 1 alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis
58. The effect of calcitriol on patients with postmenopausal osteoporosis with special reference to fracture frequency
59. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older
60. Calcitriol treatment is not effective in postmenopausal osteoporosis
61. Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study
62. Effects of 2 years' treatment of osteoporosis with 1 alpha-hydroxy vitamin D3 on bone mineral density and incidence of fracture: A placebo-controlled, double-blind prospective study
63. 1-alpha-hydroxyvitamin D3 treatment decreases bone turnover and modulates calcium-regulating hormones in early postmenopausal women
64. Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial
65. Osteoporosis
66. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease
67. Prevention and treatment of postmenopausal osteoporosis. National Consensus of the "Belgian Bone Club," November 1996
68. Prevention and management of osteoporosis: Consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 4. Calcium nutrition and osteoporosis
69. Osteoporosis (OP): Calcium (Ca) and vitamin D for the treatment of corticosteroid-induced osteoporosis
70. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
71. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk
72. Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin
73. Prevention of nonvertebral fractures by alendronate. A meta-analysis
74. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis
75. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
76. Treatment with alendronate prevents fractures in women at highest risk: Results from the Fracture Intervention Trial
77. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
78. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy
79. Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis
80. The prevention of early postmenopausal bone loss by cyclical etidronate therapy: A 2-year, double-blind, placebo-controlled study
81. The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: Results of three years of treatment
82. The effect of a modified etidronate cyclical regimen on postmenopausal osteoporosis: A four-year study
83. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial
84. Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis: A meta-analysis of published clinical trials
85. Prevention and management of osteoporosis: Consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 9. Calcitonin in the treatment of osteoporosis
86. Calcitonin for prevention and treatment of postmenopausal osteoporosis
87. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study
88. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
89. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
90. Bone histomorphometry in hypogonadal and eugonadal men with spinal osteoporosis
91. Male osteoporosis
92. Androgen supplementation in eugonadal men with osteoporosis-effects of 6 months of treatment on bone mineral density and cardiovascular risk factors
93. Testosterone therapy in glucocorticoid-treated men
94. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men
95. Effect of testosterone treatment on bone mineral density in men over 65 years of age